Ixaka
Teddy JÉGU has a diverse work experience spanning different roles and industries. Teddy is currently working at Ixaka as the Associate Director - Drug Discovery Research and Head of Biology. Prior to that, they worked at Combined Therapeutics Inc as the Preclinical Project Leader & Principal Scientist in Immuno-Oncology, and earlier as the Preclinical Project Manager in the same field. Teddy also has experience at Cellenion, where they worked as the Molecular Biology & NGS Leader and as a Senior Scientist in Molecular Biology & NGS. Before that, they were a Postdoctoral Research Fellow at Harvard Medical School. Teddy JÉGU started their career as a PHD Student at Université Paris-Saclay and also completed internships at Université Paris-Saclay, Institut Pasteur, and Gustave Roussy.
Teddy Jégu pursued their education in the field of Molecular Biology. Teddy started their academic journey in 2007 at the University of South Brittany, where they obtained a Bachelor of Science (BS) degree in Cell/Cellular and Molecular Biology in 2010. Following this, they enrolled at Pierre and Marie Curie University from 2010 to 2012, where they completed a Master of Science (MS) degree in the same field. To further their expertise, Teddy then joined Université Paris-Saclay in 2012 and successfully achieved a Doctor of Philosophy (PhD) degree in Molecular Biology in 2015.
Previous companies
This person is not in any offices
Ixaka
1 followers
Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.